Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J Turner

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|March 7, 2013
Boardroom ethics and the syndrome of senior silenceJohn J Turner
BMJ (Clinical Research Ed.)|June 9, 2007
Lessons from the disasterJohn J Turner
BMJ (Clinical Research Ed.)|February 1, 2013
Proposed model of early dementia screening cannot be validJohn J Turner
BMJ (Clinical Research Ed.)|January 29, 2005
The GMC: expediency before principle: GMC reforms may damage the NHSJohn J Turner
Nucleic Acids Research|January 11, 2005
Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptidesJohn J Turner, Andrey A Arzumanov, Michael J Gait
Current Opinion in Molecular Therapeutics|April 14, 2006
Oligonucleotide analogs as antiviral agentsMartin M Fabani, John J Turner, Michael J Gait
Age and Ageing|April 9, 2002
Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremiaNicola J Curtis, Charles van Heyningen, John J Turner
Nucleic Acids Research|September 28, 2011
Methods for L-ribooligonucleotide sequence determination using LCMSJohn J Turner, Johannes S Hoos, Stefan Vonhoff, et al.
Current Protocols in Nucleic Acid Chemistry|April 23, 2008
Disulfide conjugation of peptides to oligonucleotides and their analogsJohn J Turner, Donna Williams, David Owen, et al.
Biochimica Et Biophysica Acta|December 13, 2005
Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell deliveryJohn J Turner, Martin Fabani, Andrey A Arzumanov, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|March 7, 2013
Boardroom ethics and the syndrome of senior silenceJohn J Turner
BMJ (Clinical Research Ed.)|June 9, 2007
Lessons from the disasterJohn J Turner
BMJ (Clinical Research Ed.)|February 1, 2013
Proposed model of early dementia screening cannot be validJohn J Turner
BMJ (Clinical Research Ed.)|January 29, 2005
The GMC: expediency before principle: GMC reforms may damage the NHSJohn J Turner
Nucleic Acids Research|January 11, 2005
Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptidesJohn J Turner, Andrey A Arzumanov, Michael J Gait
Current Opinion in Molecular Therapeutics|April 14, 2006
Oligonucleotide analogs as antiviral agentsMartin M Fabani, John J Turner, Michael J Gait
Age and Ageing|April 9, 2002
Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremiaNicola J Curtis, Charles van Heyningen, John J Turner
Nucleic Acids Research|September 28, 2011
Methods for L-ribooligonucleotide sequence determination using LCMSJohn J Turner, Johannes S Hoos, Stefan Vonhoff, et al.
Current Protocols in Nucleic Acid Chemistry|April 23, 2008
Disulfide conjugation of peptides to oligonucleotides and their analogsJohn J Turner, Donna Williams, David Owen, et al.
Biochimica Et Biophysica Acta|December 13, 2005
Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell deliveryJohn J Turner, Martin Fabani, Andrey A Arzumanov, et al.
Pageof 2